Myeloma Multiple

Oncology
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Karyopharm Therapeutics
2 programs
1
1
SelinexorPhase 21 trial
CyclophosphamidePhase 1/21 trial
Active Trials
NCT03191981WithdrawnEst. Aug 2017
NCT04843579TerminatedEst. Dec 2022
Cartesian Therapeutics
1 program
1
Descartes 08Phase 21 trial
Active Trials
NCT04816526TerminatedEst. Nov 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Karyopharm TherapeuticsSelinexor
Cartesian TherapeuticsDescartes 08
Karyopharm TherapeuticsCyclophosphamide

Clinical Trials (3)

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

Start: Dec 2021Est. completion: Dec 2022
Phase 2Terminated

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Start: Dec 2021Est. completion: Nov 2022
Phase 2Terminated

Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma

Start: Aug 2017Est. completion: Aug 2017
Phase 1/2Withdrawn

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space